Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) has shared an announcement.
Ab&B Bio-Tech CO., LTD. JS has announced the commencement of Phase III clinical trials for its Lyophilized Human Rabies Vaccine (Human Diploid Cell), following approvals from the National Medical Products Administration of China. The vaccine candidate, which has shown a promising safety profile in Phase I trials, is developed under three immunization regimens and is based on human diploid cells, considered the ‘gold standard’ by WHO. This development marks a significant step in the company’s strategic focus on premium vaccines, potentially impacting its market positioning both domestically and internationally.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods. The company aims to replace traditional and imported vaccines in China and establish a presence in international markets, with products including a quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.
Average Trading Volume: 206,786
Find detailed analytics on 2627 stock on TipRanks’ Stock Analysis page.